The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies of mice catabolism of exogenous human Lp(a) have yielded mixed results, with some demonstrating LDLR-dependent and some LDLR-independent clearance.
“Although mice do not produce endogenous Lp(a), studies of their catabolism of exogenous human Lp(a) have also yielded mixed results, with some demonstrating LDLR-dependent35,36 and some LDLR-independent25,32 clearance.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [32]
Other studies have found no influence of LDLR on cellular Lp(a) binding or uptake in vitro.
“However, other studies have found no influence of LDLR on cellular Lp(a) binding or uptake in vitro31-34.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [32]
Multiple studies of LDLR in cells, animal models, and humans have provided inconsistent or conflicting results.
“Multiple studies of the LDL receptor (LDLR) in cells27-34, animal models25,32,35,36, and humans10,28,37-48 have provided inconsistent or conflicting results.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521
Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461
Flagged first, then by citations
Research works printed but not linked: 20
- Tsimikas, 2018, NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis, J Am Coll Cardiol, 71, 177, 10.1016/j.jacc.2017.11.014 · DOI
- McCormick, 2019, Lipoprotein(a) catabolism: a case of multiple receptors, Pathology, 51, 155, 10.1016/j.pathol.2018.11.003 · DOI · Paper page
- Lambert, 2017, The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies, Clin Sci (Lond), 131, 261, 10.1042/CS20160403 · DOI
- Romagnuolo, 2015, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor, J Biol Chem, 290, 11649, 10.1074/jbc.M114.611988 · DOI · Paper page
- Raal, 2016, PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role, J Lipid Res, 57, 1086, 10.1194/jlr.P065334 · DOI
- Romagnuolo, 2017, Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9, PLoS One, 12, 10.1371/journal.pone.0180869 · DOI
- Villard, 2016, PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab, J Am Coll Cardiol Basic Trans Science, 1, 419
- Sharma, 2017, Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a), Circ Res, 120, 1091, 10.1161/CIRCRESAHA.116.310272 · DOI · Paper page
- Rader, 1995, The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans, J Clin Invest, 95, 1403, 10.1172/JCI117794 · DOI · Paper page
- Reyes-Soffer, 2017, Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans, Circulation, 135, 352, 10.1161/CIRCULATIONAHA.116.025253 · DOI · Paper page
- Watts, 2018, Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics, Eur Heart J, 39, 2577, 10.1093/eurheartj/ehy122 · DOI
- Croyal, 2018, PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate, Clin Sci (Lond), 132, 1075, 10.1042/CS20180040 · DOI
- Azuma, 2007, Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg −/− mice, Nat Biotechnol, 25, 903, 10.1038/nbt1326 · DOI · Paper page
- Thedrez, 2018, Homozygous FH patients with identical mutations variably express the LDL receptor: implications for the efficacy of evolocumab, Arterioscler Thromb Vasc Biol, 38, 592, 10.1161/ATVBAHA.117.310217 · DOI · Paper page
- Thedrez, 2016, Proprotein convertase subtilisin kexin type 9 inhibition for autosomal recessive hypercholesterolemia—brief report, Arterioscler Thromb Vasc Biol, 36, 1647, 10.1161/ATVBAHA.116.307493 · DOI
- Lambert, 2014, Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab, J Am Coll Cardiol, 64, 2299, 10.1016/j.jacc.2014.07.995 · DOI
- Tavori, 2016, PCSK9 association with lipoprotein(a), Circ Res, 119, 29, 10.1161/CIRCRESAHA.116.308811 · DOI
- Ellis, 2013, Mice with chimeric livers are an improved model for human lipoprotein metabolism, PLoS One, 8, 10.1371/journal.pone.0078550 · DOI
- Minniti, 2019, New insights from liver-humanized mice on cholesterol lipoprotein metabolism and LXR-agonist pharmacodynamics in humans, Hepatology
- Schneider, 2005, High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins, J Lipid Res, 46, 769, 10.1194/jlr.M400467-JLR200 · DOI
Cited by
Sorted by citations
Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening
Khan, T. G., Bragazzi Cunha, J., Raut, C., Burroughs, M., Vyas, H. S., Leix, K., Goonewardena, S. N., Smrcka, A. V., Speliotes, E. K., & Emmer, B. T. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119174 · Cited by 6
Metadata
- Authors
- Chemello, K., Beeské, S., Trang Tran, T. T., Blanchard, V., Villard, E. F., Poirier, B., Le Bail, J.-C., Dargazanli, G., Ho-Van-Guimbal, S., Boulay, D., Bergis, O., Pruniaux, M.-P., Croyal, M., Janiak, P., Guillot, E., & Lambert, G.
- Venue
- JACC: Basic to Translational Science
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 5
- Issue
- 6
- Pages
- 549-557
- ISSN
- 2452-302X
- PMC
- PMC7315184
- Cited by
- 30
- References
- 2
- Language
- en
- Licence
- Funders
- Agence Nationale de la Recherche (ANR-16-RHUS-0007)
- European Commission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
